- #STOCK ICONS DRUG DISCOVERY SOFTWARE#
- #STOCK ICONS DRUG DISCOVERY TRIAL#
- #STOCK ICONS DRUG DISCOVERY SERIES#
#STOCK ICONS DRUG DISCOVERY SERIES#
Recursion Pharmaceuticals, which is applying machine learning to cellular imaging data, raises $239 million in Series D financing round led by Bayer’s investment department Leaps. Sanabil Investments co-leads $123 million Series B funding round for Atomwise to support the development of its molecule identification software. Relay Therapeutics, which focuses on understanding protein motion to design drug candidates, closes $400 million IPO.
Insitro raises $143 million in Series B funding, to help drive its machine learning-based drug discovery approaches further.ĪbCellera raises $105 million in Series B funding round to expand its antibody drug discovery platform.
#STOCK ICONS DRUG DISCOVERY SOFTWARE#
More established, less health-care-focused tech companies, such as IBM, Microsoft and Google, are getting involved too.ĭrug discovery software company closes $232 million IPO backed by Bill Gates and David Shaw. Others such as Recursion Pharmaceuticals, which recently raised $436 million in its initial public offering, are generating vast amounts of bespoke data on cellular behavior in the hope that these can be mined using AI to reveal biological insights that could inform the discovery of innovative drugs. Some of these are also developing tools to accelerate the identification of small-molecule drug candidates. The company has also formed drug discovery partnerships with Bristol Myers Squibb (BMS), Sanofi, Bayer, GlaxoSmithKline, Roche and the University of Oxford (Table 2), and is building its own pipeline.Įxscientia is just one of many companies founded in the past decade around AI-based strategies for drug discovery and development, several of which have raised substantial funding recently (Table 1). That drug, a selective serotonin reuptake inhibitor (SSRI) designed to treat obsessive compulsive disorder (OCD), and the oncology drug are the first two molecules designed with the help of AI to enter clinical trials, Exscientia claims. In 2020, the company did much the same, announcing a drug candidate with Sumitomo Dainippon Pharma in Osaka, Japan, then later raising $100 millionin Series C funding.
Within 3 weeks, Exscientia, a 2012 spinoff of the University of Dundee, UK, announced a $225 million Series D financing round (Table 1), along with a $300 million equity commitment that it can draw on at its discretion. This system can computationally sort through and compare various properties of millions of potential small molecules, looking for 10 or 20 to synthesize, test and optimize in lab experiments before selecting the eventual drug candidate for clinical trials. Where it might have taken the traditional discovery process 4–5 years to come up with the drug candidate-an A2 receptor antagonist designed to help T cells fight solid tumors-it was found in 8 months by harnessing Exscientia’s ‘Centaur Chemist’ AI design platform.
The candidate was created in partnership with Exscientia, a company based in Oxford, UK, that applies artificial intelligence (AI) techniques to small-molecule drug discovery.
#STOCK ICONS DRUG DISCOVERY TRIAL#
In April of this year, the German biotechnology company Evotec announced a phase 1 clinical trial on a new anticancer molecule.